現在位置首頁 > 博碩士論文 > 詳目
  • 同意授權
論文中文名稱:轉染方法的探討與回顧 [以論文名稱查詢館藏系統]
論文英文名稱:Discussion and review of transfection methods [以論文名稱查詢館藏系統]
院校名稱:臺北科技大學
學院名稱:工程學院
系所名稱:生化與生醫工程研究所
畢業學年度:101
出版年度:102
中文姓名:楊琳
英文姓名:Lin Yang
研究生學號:99688014
學位類別:碩士
語文別:中文
口試日期:2013-04-26
論文頁數:82
指導教授中文名:侯劭毅
口試委員中文名:王勝仕;黃志宏
中文關鍵詞:轉染技術病毒載體非病毒載體化學方法物理方法
英文關鍵詞:transfectionviral vector methodnon-viral vector methodchemical methodphysical method
論文中文摘要:基因轉殖也可稱為轉染技術(transfection)是將目標基因引入到真核細胞,並使之增殖和表達的一種技術。核酸導入到細胞中是生命科學及基因工程中經常使用並且是最有價值的工具。基因轉殖除了可提供研究特定基因的功能,也有應用在農業和醫學上。基因轉殖已經利用病毒、非病毒載體的方法,以及物理方法。病毒載體是採用複製缺陷型病毒載體介導基因轉移,此類載體如腺病毒,腺相關病毒,逆轉錄病毒和單純皰疹病毒等病毒。病毒載體的高效率基因運送是他們主要的優點。非病毒載體包括陽離子脂質體,陽離子聚合物,合成肽和天然存在的化合物。這些非病毒載體高效率地運送基因到體外培養的細胞中。物理方法則是利用機械壓力、電擊或水動力使細胞膜瞬時地滲透,此時DNA傳送導入靶細胞。局部基因傳遞它們比病毒和非病毒為基礎的系統是簡單的和非常有效的。每種方法的轉染效率都不相同,同一種方法應用在不同研究上其轉染效率是不盡相同的,為了讓研究者可以對轉染技術所做的研究其轉染效率有所了解,對於設計實驗上有幫助,因此在本篇論文中,將提及的內容為: (i) 將介紹22種轉染方法; (ii) 解釋設計病毒,非病毒,物理基因傳遞方法的基本原理; (iii) 研究綜述轉基因技術的最新進展; (iv) 討論每一個最常用的基因傳遞方法的優點和缺點; 及(v) 提供未來前景。
論文英文摘要:Transfection is a technology of introducing the target gene into eukaryotic cell and the target gene amplified and expressed. Nucleic acids are transducted into cells, which is commonly used and the valuable tools in life science and genetic engineering. Gene transfection can not only be provided the research of specific gene function but also used in agriculture and medical science. Gene transfection has be search for using viral, non-viral vector and physical methods. Viral vector-mediated gene transfer employs replication-deficient viruses such as adenovirus, adeno-associated virus, retrovirus, herpes simplex virus, etc. High gene delivery efficiency of viral vectors of is their major advantage. Up to date, the nonviral vectors has been developed include cationic liposomes, cationic polymers, synthetic peptides and natural compounds. These nonviral vectors appear to be highly effective in gene delivery to cultured cells in vitro but are significantly less effective in vivo. Physical methods that are using physical force are mechanical pressure, electric shock or hydrodynamic force to transiently permeate the cell membrane to transfer DNA into target cells. They are simpler than viral- and nonviral-based systems and highly effective for localized gene delivery. The transfection efficiency of each methods are not the same. The same method applied in different studies that the results of the transfection efficiency are not the same. In order to make researchers better understanding the efficiency of the study which is made by transfection technology. For designing experiments it can be helpful. Therefore, the objectives in this review are (i) introducing twenty two transfection methods; (ii) explaining the rationale for the design of viral, nonviral and physical methods for gene delivery;(iii) providing a summary on recent advances in gene transfer technology; (iv) discussing advantages and disadvantages of each of the most commonly used gene delivery methods; and (v) providing future perspectives.
論文目次:中文摘要 i
英文摘要 ii
誌謝 iv
目錄 v
表目錄 vii
圖目錄 viii
第一章 緒論 1
1.1基因轉殖(Transfection) 1
1.2基因轉殖技術之應用 2
第二章 基因重組病毒的方法 4
2.1腺病毒(Adenoviruses) 8
2.2腺相關病毒(Adenoassociated viruses) 11
2.3逆轉錄病毒(Retroviruses) 13
2.4慢病毒 (Lentiviruses) 16
2.5泡沫病毒載體 (Foamy Viral Vectors) 18
2.6單純皰疹病毒(Herpes simplex viruses) 和
牛痘病毒( Vaccinia viruses) 18
2.7猿猴病毒40 (Simian virus 40, SV40) 20
2.8 pED 20
2.9靶向基因轉移和可調控表達(Targeted gene transfer and
regulatable expression) 21
2.10不同的病毒系統整理與比較 23
第三章 化學的方法 25
3.1二乙基氨基乙基-葡聚醣 (DEAE (Diethylaminoethyl)
-dextran) 25
3.2磷酸鈣(Calcium-Phosphate) 26
3.3脂質體轉染(Lipofection) 27
3.4聚合物(Polymer) 30
第四章 物理的方法 33
4.1顯微注射(Microinjection) 33
4.2基因槍微粒輸送(Biolistic Particle Delivery) 33
4.3電穿孔(Electroporation) 35
4.4 Sonoporation 37
4.5激光輔助方法(Laser-Assisted Method) (Photoporation) 38
4.6磁轉 (Magnetofection) 39
4.7流體動力基因傳遞 (Hydrodynamic Gene Delivery)
(Hydroporation) 40
4.8細胞核基因殖入系統 (NucleofectorTM) 42
4.9針頭注射(Injection) 43
第五章 轉染方法的優缺點 49
第六章 結論及展望 53
參考文獻 56
論文參考文獻:[1] Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, Guggino WB, Cutting GR, Carter BJ, Flotte TR. 1996. In vivo model of adenoassociated virus vector persistence and rescue. J Virol. 70(5):3235–41.
[2] Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, Wintergerst U, Buckley RH, Bregni M, Marktel S, Valsecchi MG, Rossi P, Ciceri F, Miniero R, Bordignon C, Roncarolo MG. 2009. Gene therapy for immuno-deficiency due to adenosine deaminase deficiency. N Engl J Med. 360(5):447–58.
[3] Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn A, Peschanski MR. 1993. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet. 3(3):224–8.
[4] Alba R, Bosch A, Chillon M. 2005. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 12(Suppl 1):S18–27.
[5] Alexander WA, Moss B, Fuerst TR. 1992. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol. 66(5):2934–42.
[6] Aliño SF, Herrero MJ, Noguera I, Dasí F, Sánchez M. 2007. Pig liver gene therapy by noninvasive interventionist catheterism. Gene Ther. 14(4):334–43.
[7] Arad U, Zeira E, El-Latif MA, Mukherjee S, Mitchell L, Pappo O, Galun E, Oppenheim A. 2005. Liver-targeted gene therapy by SV40-based vectors using the hydrodynamic injection method. Hum Gene Ther. 16(3):361–71.
[8] Arnberg N. 2009. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol. 19(3):165–78.
[9] Arnold GS, Sasser AK, Stachler MD, Bartlett JS. 2006. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther. 14(1):97–106.
[10] Avery OT, MacLeod CM, McCarty M. 1979. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: inductions of transformation by a deoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med. 149:297–326.
[11] Avrameas A, Ternynck T, Nato F, Buttin G, Avrameas S. 1998. Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules. Proc Natl Acad Sci U S A. 95(10):5601–6.
[12] Bakker AC, Van de Loo FA, Joosten LA, Bennink MB, Arntz OJ, Dmitriev IP, Kashentsera EA, Curiel DT, van den Berg WB. 2001. A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. Gene Ther. 8(23):1785–93.
[13] Balicki D, Beutler E. 1997. Histone H2A significantly enhances in vitro DNA transfection. Mol Med. 3(11):782–7.
[14] Balicki D, Putnam CD, Scaria PV, Beutler E. 2002. Structure and function correlation in histone H2A peptide-mediated gene transfer. Proc Natl Acad Sci U S A. 99(11):7467–71.
[15] Bangari DS, Mittal SK. 2006. Development of nonhuman adenoviruses as vaccine vectors. Vaccine. 24(7):849–62.
[16] Bangham AD, Standish MM, Watkins JC. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 13(1):238–52.
[17] Bao S, Thrall BD, Gies RA, Miller DL. 1998. In vivo transfection of melanoma cells by lithotripter shock waves. Cancer Res. 58(2):219–21.
[18] Bao S, Thrall BD, Miller DL. 1997. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med. Biol. 23(6):953–9.
[19] Barquinero J, Eixarch H, Pérez-Melgosa M. 2004. Retroviral vectors: new applications for an old tool. Gene Ther. 11 (Suppl 1):S3–9.
[20] Barreiro O, Aguilar Rio J, Tejera E, Megías D, de Torres-Alba F, Evangelista A, Sánchez-Madrid F. 2009. Specific targeting of human inflamed endothelium and in situ vascular tissue transfection by the use of ultrasound contrast agents. JACC Cardiovasc Imaging. 2(8):997–1005.
[21] Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. 1999. Targeted adenoassociated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′gamma) 2 antibody. Nat Biotechnol. 17(2):181–6
[22] Bauer TR Jr, Allen JM, Hai M, Tuschong LM, Khan IF, Olson EM, Adler RL, Burkholder TH, Gu YC, Russell DW, Hickstein DD. 2008. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med. 14(1):93–7.
[23] Bekeredjian R, Chen S, Frenkel PA, Grayburn PA, Shohet RV. 2003. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation. 108(8):1022–6.
[24] Bekeredjian R, Grayburn PA, Shohet RV. 2005. Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine. J Am Coll Cardiol. 45(3):329–35.
[25] Bett AJ, Haddara W, Prevec L, Graham FL. 1994. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 91(19):8802–6.
[26] Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. 1995. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270(5235):475–80.
[27] Blömer U, Naldini L, Verma IM, Trono D, Gage FH. 1996. Applications of gene therapy to the CNS. Hum Mol Genet. 5(spec no.):1397–404.
[28] Bodles-Brakhop AM, Heller R, Draghia-Akli R. 2009. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther. 17(4):585–92.
[29] Bouard D, Alazard-Dany D, Cosset FL. 2009. Viral vectors: from virology to transgene expression. Br J Pharmacol. 157(2):153–65.
[30] Boussif O, Lezoualc’h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 92(16):7297–301.
[31] Brunetti-Pierri N, Palmer DJ, Mane V, Finegold M, Beaudet AL, Ng P. 2005. Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helperdependent adenoviral vectors. Mol Ther. 12(1):99–106.
[32] Brunetti-Pierri N, Stapleton GE, Palmer DJ, Zuo Y, Mane VP, Finegold MJ, Beaudet AL, Leland MM, Mullins CE, Ng P. 2007. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther. 15(4):732–40.
[33] Buch PK, Bainbridge JW, Ali RR. 2008. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther. 15(11):849–57.
[34] Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. 2008. Recent developments in adeno-associated virus vector technology. J Gene Med. 10(7):717–33.
[35] Burcin MM, Schiedner G, Kochanek S, Tsai SY, O’Malley BW. 1999. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA. 96(2):355–60.
[36] Burton EA, Bai Q, Goins WF, Glorioso JC. 2002. Replication-defective genomic herpes simplex vectors: design and production. Curr Opin Biotechnol. 13(5):424–8.
[37] Butow RA, Fox TD. 1990. Organelle transformation: shoot first, ask questions later. Trends Biochem Sci 15(12):465–8.
[38] Byrnes AP, Rusby JE, Wood MJ, Charlton HM. 1995. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66(4):1015–24.
[39] Calmon MF, de Souza AT, Candido NM, Raposo MI, Taboga S, Rahal P, Nery JG. 2012. A systematic study of transfection efficiency and cytotoxicity in HeLa cells using iron oxide nanoparticles prepared with organic and inorganic bases. Colloids and Surf B: Biointerfaces 100:177– 84.
[40] Carroll MW, Moss B. Poxviruses as expression vectors. 1997. Curr. Opin .Biotechnol. 8(5):573–7.
[41] Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, Zuleger CL, Bridges AJ, Schalch HG, Kim KM, Hank JA, Mahvi DM, Albertini MR. 2007. A phase I study of immunization using particlemediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res. 13(2 Pt1):540–9.
[42] Cearley CN, Vandenberghe LH, Parente MK, Carnish ER, Wilson JM, Wolfe JH. 2008. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Molec Ther. 16(10):1710–8.
[43] Chakravarty P, Qian W, El-Sayed MA, Prausnitz MR. 2010. Delivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses. Nat Nanotechnol. 5(8):607–11.
[44] Check E. 2003. Second cancer case halts gene-therapy trials. Nature. 421(6921):305.
[45] Chemin I, Moradpour D, Wieland S, Offensperger WB, Walter E, Behr JP, Blum HE. 1998. Liver-directed gene transfer: a linear polyethlenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo. J Viral Hepat. 5(6):369–75.
[46] Chen L, Zhu F, Li J, Lu H, Jiang H, Sarkar R, Arruda VR, Wang J, Zhao J, Pierce GF, Ding Q, Wang X, Wang H, Pipe SW, Liu XQ, Xiao X, Camire RM, Xiao W. 2007. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther. 15(10):1856–62.
[47] Chen N, Zhang Q, Yu YA, Stritzker J, Brader P, Schirbel A, Samnick S, Serganova I, Blasberg R, Fong Y, Szalay AA. 2009. A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol Med. 15(5-6):144-151.
[48] Chen S, Ding JH, Bekeredjian R, Yang BZ, Shohet RV, Johnston SA, Hohmeier HE, Newgard CB, Grayburn PA. 2006. Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology. Proc Natl Acad Sci U S A. 103(22):8469–74.
[49] Choate KA, Khavari PA. 1997. Direct cutaneous gene delivery in a human genetic skin disease. Hum Gene Ther. 8(14):1659–65.
[50] Condiotti R, Curran MA, Nolan GP, Giladi H, Ketzinel-Gilad M, Gross E, Galun E. 2004. Prolonged liver-specific transgene expression by a nonprimate lentiviral vector. Biochem Biophys Res Commun. 320(3):998–1006.
[51] Coura RS, Nardi NB. 2007. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J. 4:99.
[52] Cox WI, Tartaglia J, Paoletti E. 1992. Poxvirus recombinants as live vaccines. In Recombinant Poxviruses (Binns, M. M. and Smith, G. L., eds.) CRC Press, Boca Raton 123–162.
[53] Cregan SP, MacLaurin J, Gendron TF, Callaghan SM, Park DS, Parks RJ, Graham FL, Morley P, Slack RS. 2000. Helper-dependent adenovirus vectors: their use as a gene delivery system to neurons. Gene Ther. 7(14):1200–9.
[54] Cronin J, Zhang XY, Reiser J. 2005. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 5(4):387–98.
[55] Cuchet D, Potel C, Thomas J, Epstein AL. 2007. HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin Biol Ther. 7(7):975–95.
[56] Cullen BR, Garrett ED. 1992. A comparison of regulatory features in primate lentiviruses. AIDS Res. Hum. Retroviruses 8(3):387–393.
[57] Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ, Ciccarone VC. 2004. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 33(2):95–103.
[58] Daniel R, Smith JA. 2008. Integration site selection by retroviral vectors: molecular mechanism and clinical consequences. Hum Gene Ther. 19(6):557–68.
[59] Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. 1993. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet. 3(3):219–23
[60] Davidson BL, Stein CS, Heth JA, Martins I, Kotini RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA. 2000. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA. 97(7):3428–32.
[61] Davies MV, Kaufman RJ. 1992. Internal translation initiation in the design of improved expression vectors. Curr Opin Biotech. 3(5):512–7.
[62] Daya S, Berns KI. 2008. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 21(4):583–93.
[63] Dedieu JF, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud JM, Aubailly N, Orsini C, Guillaume JM, Opolon P, Delaere P, Perricaudet M, Yeh P. 1997. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol. 71(6):4626–37.
[64] Delenda C. 2004. Lentiviral vectors: optimization of packaging, transduction and gene expression. J Gene Med. 6 (Suppl 1):S125–38.
[65] DePolo NJ, Reed JD, Sheridan PL, Townsend K, Sauter SL, Jolly DJ, Dubensky TW Jr. 2000. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther. 2(3):218–22.
[66] Dimitrov DS, Norwood D, Stantchev TS, Feng Y, Xiao X, Broder CC. 1999. A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages. Virology 259(1):1–6.
[67] Dobson J. 2006. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 13(4):283–7.
[68] Doenecke A, Kromer A, Scherer MN, Schlitt HJ, Geissler EK. 2010. AAV plasmid DNA simplifies liver-directed in vivo gene therapy: comparison of expression levels after plasmid DNA-, adeno-associated virus- and adenovirus-mediated liver transfection. J Gene Med. 12(10):810–7.
[69] Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. 2006. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine. 24(21):4475–81.
[70] Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. 1998. A third-generation lentivirus vector with a conditional packaging system. J Virol. 72(11):8463–71.
[71] Durcan N, Murphy C, Cryan SA. 2008. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm. 5(4):559–66.
[72] Earl P, Moss B. 1991. Generation of recombinant vaccinia viruses. Current Protocols in Molecular Biology, Wiley-Interscience, New York 16.15.1–16.18.10.
[73] Eastman SJ, Baskin KM, Hodges BL, Chu Q, Gates A, Dreusicke R, Anderson S, Scheule RK. 2002. Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum Gene Ther. 13(17):2065–77.
[74] El-Aneed A. 2004. An overview of current delivery systems in cancer gene therapy. J Control Release. 94(1):1– 14.
[75] Elroy-Stein O, Moss B. 1992. Gene expression using the vaccinia virus/T7 RNA polymerase hybrid system. Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience 16.19.1–16.19.12.
[76] Engelhardt JF, Ye X, Doranz B, Wilson JM. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A. 91(13):6196–200.
[77] Epstein AL. 2009. Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors. Gene Ther. 16(6):709–15.
[78] Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. 1998. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res. 15(9):1332–9.
[79] Erlwein O, McClure MO. 2010. Progress and prospects: foamy virus vectors enter a new age. Gene Ther. 17(12):1423–9.
[80] Fabre JW, Grehan A, Whitehorne M, Sawyer GJ, Dong X, Salehi S, Eckley L, Zhang X, Seddon M, Shah AM, Davenport M, Rela M. 2008. Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava. Gene Ther. 15(6):452–62.
[81] Favard C, Dean DS, Rols MP. 2007. Electrotransfer as a nonviral method of gene delivery. Curr Gene Ther. 7(1):67–77.
[82] Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. 1987. Lipofection: a highly efficient, lipid-mediated DNA transfection procedure. Proc Natl Acad Sci U S A. 84(21):7413–7.
[83] Fenner F. 1992. Vaccinia virus as a vaccine, and poxvirus pathogenesis. In Recombinant Poxviruses (Binns, M. M. and Smith, G. L., eds.) CRC Press, Boca Raton, 1–43.
[84] Flexner C, Moss B. 1997. Vaccinia virus as a live vector for expression of immunogens. 2nd ed. New Generation Vaccines, Marcel Dekker, New York 297–314.
[85] Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY. 2009. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther. 17(7):1125–35.
[86] Fu H, Muenzer J, Samulski RJ, Breese G, Sifford J, Zeng X, McCarty DM. 2003. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAVmediated transgene expression in mouse brain. Molec Ther. 8(6):911–7.
[87] Fuerst TR, Earl PL, Moss B. 1987. Use of hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol. 7(7):2538–44.
[88] Fuerst TR, Fernandez MP, Moss B. 1989. Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector. Proc Natl Acad Sci U S A. 86(8):2549–2553.
[89] Fuerst TR, Niles EG, Studier FW, Moss B. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A. 83(21):8122–8126.
[90] Glorioso JC, Fink DJ. 2009. Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther. 17(1):13–8.
[91] Glover DJ, Lipps HJ, Jans DA. 2005. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6(4):299–310.
[92] Goula D, Remy JS, Erbacher P, Wasowicz M, Levi G, Abdallah B, Demeneix BA. 1998. Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene Ther. 5(5):712–7.
[93] Graham FL, van dee Eb A J. 1973.Transformation of rat cells by DNA of human adenovirus 5. Virology 54(2):536-9.
[94] Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 36(1):59–74.
[95] Green JJ, Shi J, Chiu E, Leshchiner ES, Langer R, Anderson DG. 2006. Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjugate Chem. 17(5):1162-9.
[96] Guo H, Leung JC, Chan LY, Tsang AW, Lam MF, Lan HY, Lai KN. 2007. Ultrasound-contrast agent mediated naked gene delivery in the peritoneal cavity of adult rat. Gene Ther. 14(24):1712–20.
[97] Habib NA, Ding SF, el-Masry R, Mitry RR, Honda K, Michail NE, Dalla Serra G, Izzi G, Greco L, Bassyouni M, el-Toukhy M, Abdel-Gaffar Y. 1996. Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev. 20(2):103–7.
[98] Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debré M, Casanova JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. 2010. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 363(4):355–64.
[99] Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 346(16):1185–93.
[100] Haensler J, Szoka FC Jr. 1993. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem. 4(5):372–9.
[101] Hahn P, Scanlan E. 2010. Gene delivery into mammalian cells: An overview on existing approaches employed in vitro and in vivo. Top Curr Chem. 296:1-13.
[102] Harding TC, Geddes BJ, Murphy D, Knight D, Uney JB. 1998. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol. 16(6):553–5.
[103] Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobart P, Norman J, Manthorpe M. 1996. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther. 7(10):1205–17.
[104] Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD, Uytdehaag F, Quax PH, Logtenberg T, Mehtali M, Bout A. 2002. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol. 76(9):4612–20.
[105] Hayashi S, Mizuno M, Yoshida J, Nakao A. 2009. Effect of sonoporation on cationic liposome-mediated IFNbeta gene therapy for metastatic hepatic tumors of murine colon cancer. Cancer Gene Ther. 16(8):638–43.
[106] He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. 1998. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 95(5):2509–14.
[107] Heller LC, Ugen K, Heller R. 2005. Electroporation for targeted gene transfer. Expert Opin Drug Deliv. 2(2):255–68.
[108] Heller R, Jaroszeski MJ, Glass LF, Messina JL, Rapaport DP, DeConti RC, Fenske NA, Gilbert RA, Mir LM, Reintgen DS. 1996. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer. 77(5):964–71.
[109] Hermens WT, Verhaagen J. 1998. Viral vectors, tools for gene transfer in the nervous system. Prog Neurobiol. 55(4):399–432.
[110] Herweijer H, Wolff JA. 2007. Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Ther. 14(2):99–107.
[111] Hickman MA, Malone RW, Lehmann-Bruinsma K, Sih TR, Knoell D, Szoka FC, Walzem R, Carlson DM, Powell JS. 1994. Gene expression following direct injection of DNA into liver. Hum Gene Ther. 5(12):1477–83.
[112] Hou C-C, Wang W, Huang XR, Fu P, Chen TH, Sheikh-Hamad D, Lan HY. 2005. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol. 166(3):761–71.
[113] Howarth JL, Glover CP, Uney JB. 2009. HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease. J Neurochem. 108(4):945–51.
[114] Howarth JL, Kelly S, Keasey MP, Glover CP, Lee YB, Mitrophanous K, Chapple JP, Gallo JM, Cheetham ME, Uney JB. 2007. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol Ther. 15(6):1100–5.
[115] Howarth JL, Lee YB, Uney JB. 2010. Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol Toxicol. 26(1):1–20.
[116] Hsu CYM, Uludağ H. 2012. Cellular uptake pathways of lipid-modified cationic polymers in gene delivery to primary cells. Biomaterials 33:7834-7848.
[117] Huber PE, Jenne J, Debus J, Wannenmacher MF, Pfisterer P. 1999. A comparison of shock wave and sinusoidal-focused ultrasound-induced localized transfection of HeLa cells. Ultrasound Med Biol. 25(9):1451–7.
[118] Hynynen K, McDannold N, Martin H, Jolesz FA, Vykhodtseva N. 2003. The threshold for brain damage in rabbits induced by bursts of ultrasound in the presence of an ultrasound contrast agent (Optison). Ultrasound Med Biol. 29(3):473–81.
[119] Kafri T, van PH, Gage FH, Verma IM. 2000. Lentiviral vectors: regulated gene expression. Mol Ther. 1(6):516–21.
[120] Kamimura K, Guisheng Z, Liu D. 2010. Image-guided, intravascular hydrodynamic gene delivery to skeletal muscle in pigs. Mol Ther. 18(1):93–100.
[121] Kamimura K, Suda T, Xu W, Zhang G, Liu D. 2009. Image-guided, lobe-specific hydrodynamic gene delivery to swine liver. Mol Ther. 17(3):491–9.
[122] Kamimura K, Suda T, Zhang G, Liu D. 2011. Advances in gene delivery systems. Pharmaceut Med. 25(5):293–306.
[123] Karra D, Dahm R. 2010. Transfection techniques for neuronal cells. The Journal of Neuroscience 30(18):6171–7.
[124] Kaufman RJ. 2000. Overview of vector design for mammalian gene expression. Mol Biotechnol. 16(2):151-60.
[125] Kaur T, Slavcev RA, Wettig SD. 2009. Addressing the challenge: current and future directions in ovarian cancer therapy. Curr Gene Ther. 9(6):434–58.
[126] Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC. 2008. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol. 180(10):7019–27.
[127] Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME. 1996. Ultrasound-mediated transfection of mammalian cells. Hum Gene Ther. 7(11):1339–46.
[128] Kim JA, Lee WG, Jung NC. 2010. Enhanced electro-mediated gene delivery using carrier genes. Bioelectrochemistry 78(2):186–190.
[129] Kim TK, Eberwine JH. 2010. Mammalian cell transfection: the present and the future. Anal Bioanal Chem. 397(8):3173–8.
[130] Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. 1998. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol. 72(1):811–6.
[131] Kingston RE. 2003. Introduction of DNA into Mammalian Cells. Current Protocols in Molecular Biology. 9.0.1-9.0.5.
[132] Klein RM, Wolf ED, Wu R, Sanford JC. 1992. High-velocity microprojectiles for delivering nucleic acids into living cells: 1987. Biotechnology. 24:384–6.
[133] Kobayashi N, Rivas-Carrillo JD, Soto-Gutierrez A, Fukazawa T, Chen Y, Navarro-Alvarez N, Tanaka N. 2005. Gene delivery to embryonic stem cells. Birth Defects Research (Part C) 75(1):10–18.
[134] Koczot FJ, Carter BJ, Garon CF, Rose JA. 1973. Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA. Proc Natl Acad Sci U S A. 70(1):215–9.
[135] Kodama T, Aoi A, Watanabe Y, Horie S, Kodama M, Li L, Chen R, Teramoto N, Morikawa H, Mori S, Fukumoto M. 2010. Evaluation of transfection efficiency in skeletal muscle using nano/microbubbles and ultrasound. Ultrasound Med Biol. 36(7):1196–205.
[136] Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, Oette SM, Payne JM, Muhammad O, Ziady AG, Moen RC, Cooper MJ. 2004. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther. 15(12):1255–69.
[137] Lee D, Upadhye K, Kumta PN. 2012. Nano-sized calcium phosphate (CaP) carriers for non-viral gene delivery. Materials Science and Engineering: B 177(3):289–302.
[138] Lee LK, Williams CL, Devore D, Roth CM. 2006. Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides. Biomacromolecules. 7(5):1502–8.
[139] Lee RJ, Huang L. 1996. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem. 271(14):8481–7.
[140] Leitner WW, Ying H, Restifo NP. 2000. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18(9-10):765-77.
[141] Lewis PF, Emerman M. 1994. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol. 68(1):510–6.
[142] Li S, Huang L. 1997. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 4(9):891–900.
[143] Liu D, Ren T, Gao X. 2003. Cationic transfection lipids. Curr Med Chem. 10(14):1307–15.
[144] Liu F, Song Y, Liu D. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6(7):1258–66.
[145] Liu Y, Yang H, Sakanishi A. 2006. Ultrasound: Mechanical gene transfer into plant cells by sonoporation. Biotechnol Adv. 24(1):1–16.
[146] Lu QL, Liang H-D, Partridge T, Blomley MJ. 2003. Microbubble ultrasound improves the efficiency of gene transduction in skeletal muscle in vivo with reduced tissue damage. Gene Ther. 10(5):396–405.
[147] Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, Chen Z, Merling R, Davis B, Chang YN, Dropulic B. 2004. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med. 6(9):963–73.
[148] Mackett M, Smith GL, Moss B. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 79(23):7415–9.
[149] Mackett M. 1991. Manipulation of vaccinia virus vectors. Gene Transfer and Expression Protocols 7:129–46.
[150] Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schonely K, Ni Y, Binder GK, Levine BL, MacGregor RR, June CH, Dropulic B. 2005. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther. 16(1):17–25.
[151] Manome Y, Nakamura M, Ohno T, Furuhata H. 2000. Ultrasound facilitates transduction of naked plasmid DNA into colon carcinoma cells in vitro and in vivo. Human Gene Therapy 11(11):1521–8.
[152] Manome Y, Nakayama N, Nakayama K, Furuhata H. 2005. Insonation facilitates plasmid DNA transfection into the central nervous system and microbubbles enhance the effect. Ultrasound Med Biol. 31(5):693–702.
[153] Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ. 2006. Oncolytic HSV-1 for the treatment of brain tumours. Herpes.13(3):66–71.
[154] Marshall E. 1999. Gene therapy death prompts review of adenovirus vector. Science. 286(5448):2244–5.
[155] McCarty DM, Monahan PE, Samulski RJ. 2001. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8(16):1248–54.
[156] Mehier-Humbert S, Guy RH. 2005. Physical methods for gene transfer: Improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev. 57(5):733–53.
[157] Merdan T, Kopecek J, Kissel T. 2002. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev. 54(5):715–758.
[158] Mergia A, Heinkelein M. 2003. Foamy virus vectors. Curr Top Microbiol Immunol. 277:131–59.
[159] Miao CH, Brayman AA, Loeb KR, Ye P, Zhou L, Mourad P, Crum LA. 2005. Ultrasound enhances gene delivery of human factor IX plasmid. Hum Gene Ther. 16(7):893–905.
[160] Mintzer MA, Simanek EE. 2009. Nonviral vectors for gene delivery. Chem Rev. 109(2):259–302.
[161] Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM. 1998. Development of a self-inactivating lentivirus vector. J Virol. 72(10):8150–7.
[162] Mizuguchi H, Kay MA. 1998. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 9(17):2577–83.
[163] Monahan PE, Samulski RJ. 2000. AAV vectors: is clinical success on the horizon? Gene Ther. 7(1):24–30.
[164] Montier T, Benvegnu T, Jaffrès PA, Yaouanc JJ, Lehn P. 2008. Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example. Curr Gene Ther. 8(5):296–312.
[165] Morral N, O'Neal W, Zhou H, Langston C, Beaudet A. 1997. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther. 8(10):1275–86.
[166] Moss B. 1991. Vaccinia virus: A Tool for Research and Vaccine Development. Science 252(5013):1662–7.
[167] Moss B. 1993. Poxvirus vectors: cytoplasmic expression of transferred genes. Curr Opin Gen Dev. 3(1):86–90.
[168] Moss B. 1994. Replicating and host-restricted non- replicating vaccinia virus vectors for vaccine development. Dev Biol Stand. 82:55–63.
[169] Moss B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A. 93(21):11341–8.
[170] Murphy EA, Waring AJ, Haynes SM, Longmuir KJ. 2000. Compaction of DNA in an anionic micelle environment followed by assembly into phosphatidylcholine liposomes. Nucleic Acids Res. 28(15):2986–92.
[171] Muruve DA. 2004. The innate immune response to adenovirus vectors. Hum Gene Ther. 15(12):1157–66.
[172] Muzyczka N, Warrington KH Jr. 2005. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther. 16(4):408–16.
[173] Mykhaylyk O, Antequera YS, Vlaskou D, Plank C. 2007. Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc. 2(10):2391–411.
[174] Nakashima M, Tachibana K, Iohara K, Ito M, Ishikawa M, Akamine A. 2003. Induction of reparative dentin formation by ultrasound-mediated gene delivery of growth/differentiation factor 11. Hum Gene Ther. 14(6):591–7.
論文全文使用權限:同意授權於2013-11-30起公開